2 and TGFβ levels as determined by IHC. Conclusions Taken together, the selection of CAR-T design which provided therapeutic margin in relevant murine models, addition of armoring and optimization of manufacturing enabled generation of a lead molecule which provides efficacy in relevant cell line and patient derived xenograft models of gastric, pancreatic and esophageal cancers and supports further clinical development of AZD6422.